Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 2.42 below Adc Therapeutics Sa's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 263 other companies have achieved higher Quick Ratio than Adc Therapeutics Sa in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 312, from total ranking in the second quarter 2026 at 707.

Explain Quick Ratio?
How much Cash & cash equivalents ADCT�s has?
What are ADCT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ADCT/financial-strength

https://api.csimarket.com/api/v1/companies/ADCT/fundamentals

https://api.csimarket.com/api/v1/companies/ADCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ADCT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	361.27 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-19.4 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.42	Subscribe	Subscribe	Subscribe	Subscribe
ADCT's Total Ranking	# 312	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-9.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-13.65 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 264
Healthcare Sector	# 453
Overall Market	# 1268

Quick Ratio Statistics
High	Average	Low
35.72	6.87	1.23
(Mar 31 2023)		(Jan 31, 2008)

Financial Statements
Adc Therapeutics Sa's Current Liabilities	$ 78 Millions	Visit ADCT's Balance sheet
Adc Therapeutics Sa's Cash & cash equivalent	$ 189 Millions	Visit ADCT's Balance sheet
Source of ADCT's Sales		Visit ADCT's Sales by Geography

Cumulative Adc Therapeutics Sa's Quick Ratio

ADCT's Quick Ratio for the trailling 12 Months

ADCT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	130.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-4.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.26	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3702	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	40.77 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-4.81 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ADCT Financial Strength Comparisons >> Go to Compare ADCT Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $78.12 millions, cumulative Quick Ratio decreased to 4.26 above the ADCT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Adc Therapeutics Sa. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3640 to 3702.

Explain Quick Ratio?
How much Cash & cash equivalents ADCT�s has?
What are ADCT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 428
Healthcare Sector	# 871
Within the Market	# 3702

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.86	3.39	0.32
(Dec 31 2020)		(Oct. 31, 2005)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Coya Therapeutics Inc	6.64	$ 35.802 Millions	$ 5.395 Millions
Capricor Therapeutics inc	6.61	$ 197.581 Millions	$ 29.895 Millions
Arcturus Therapeutics Holdings Inc	6.52	$ 184.817 Millions	$ 28.345 Millions
Moonlake Immunotherapeutics	6.50	$ 379.704 Millions	$ 58.430 Millions
Camp4 Therapeutics Corporation	6.27	$ 124.522 Millions	$ 19.865 Millions
Context Therapeutics Inc	6.26	$ 34.411 Millions	$ 5.501 Millions
Bridgebio Oncology Therapeutics Inc	6.18	$ 315.331 Millions	$ 51.026 Millions
Cartesian Therapeutics Inc	6.12	$ 122.975 Millions	$ 20.088 Millions
Olema Pharmaceuticals Inc	5.98	$ 413.771 Millions	$ 69.233 Millions
Summit Therapeutics Inc	5.71	$ 629.899 Millions	$ 110.226 Millions
Nurix Therapeutics Inc	5.51	$ 720.458 Millions	$ 130.742 Millions
United Therapeutics Corporation	5.51	$ 3,439.800 Millions	$ 624.300 Millions
Immuneering Corporation	5.45	$ 58.776 Millions	$ 10.791 Millions
Aquestive Therapeutics Inc	5.22	$ 90.349 Millions	$ 17.299 Millions
Sionna Therapeutics Inc	5.11	$ 83.878 Millions	$ 16.420 Millions
Gain Therapeutics inc	4.94	$ 11.698 Millions	$ 2.369 Millions
Rani Therapeutics Holdings Inc	4.91	$ 45.288 Millions	$ 9.223 Millions
Abeona Therapeutics Inc	4.87	$ 134.941 Millions	$ 27.707 Millions
Shattuck Labs Inc	4.84	$ 61.758 Millions	$ 12.758 Millions
Mereo Biopharma Group Plc	4.75	$ 26.097 Millions	$ 5.494 Millions
Spruce Biosciences Inc	4.69	$ 87.691 Millions	$ 18.710 Millions
Septerna Inc	4.56	$ 478.601 Millions	$ 104.863 Millions
Atossa Therapeutics Inc	4.37	$ 20.574 Millions	$ 4.709 Millions
Neurogene Inc	4.35	$ 78.942 Millions	$ 18.163 Millions
Entrada Therapeutics Inc	4.34	$ 112.302 Millions	$ 25.863 Millions
Gyre Therapeutics Inc	4.34	$ 86.190 Millions	$ 19.874 Millions
Cellectar Biosciences Inc	4.24	$ 24.582 Millions	$ 5.798 Millions
Foghorn Therapeutics Inc	4.19	$ 156.222 Millions	$ 37.315 Millions
Calcimedica Inc	4.12	$ 13.768 Millions	$ 3.339 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions

Date modified: 2026-11-10T11:45:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.